Bioprocess optimization of interferon β-1-a in Pichia pastoris and its improved inhibitory effect against hepatocellular carcinoma cells
DOI:
https://doi.org/10.1590/s2175-97902022e18984Palavras-chave:
Interferon-β-1a, Pichia pastoris, Expression, Cell survival, Hepatocellular carcinomaResumo
Interferon-β-1a (INF-β-1a) has gained significant attention due to its emerging applications in the treatment of different human diseases. Therefore, many researchers have attempted to produce it in large quantities and also in a biologically active form using different expression systems. In the present study, we aimed to improve the expression level of INF-β-1a by Pichia pastoris using optimization of culture conditions. The codon-optimized INF-β- 1a gene was cloned into pPICZαA plasmid under the control of alcohol oxidase I (AOX1) promoter. The protein expression was induced using different concentrations of methanol at different pHs and temperatures. The biological activity of produced protein was evaluated by anti-proliferative assay. The ideal culture conditions for the expression of INF-β-1a by P. pastoris were found to be induction with 2% methanol at pH 7.0 culture medium at 30 C which yielded a concentration of 15.5 mg/L INF-β-1a in a shake flask. Our results indicate that differences in glycosylation pattern could result in different biological activities as INF- β-1a produced by P. pastoris could significantly more reduce the cell viability of HepG-2 cells, a hepatocellular carcinoma cell line, than a commercially available form of this protein produced by CHO.
Downloads
Referências
Ahmad M, Hirz M, Pichler H, Schwab H. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. 2014;98(12):5301-5317.
Akbari V, Sadeghi HMM, Jafarian-Dehkordi A, Abedi D, Chou CP. Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli. Protein Expression Purif. 2015;116:66-74.
Akbari V, Sadeghi HMM, Jafrian-Dehkordi A, Abedi D, Chou CP. Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol. 2014;41(6):947-956.
Almo SC, Love JD. Better and faster: improvements and optimization for mammalian recombinant protein production. Curr Opin Struct Biol. 2014,26:39-43.
Asada H, Uemura T, Yurugi-Kobayashi T, Shiroishi M, Shimamura T, Tsujimoto H, et al. Evaluation of the Pichia pastoris expression system for the production of GPCRs for structural analysis. Microb Cell Fact. 2011;10(1):24.
Baneyx F. Recombinant protein expression in Escherichia coli. Curr Opin biotechnol. 1999;10(5):411-421.
Boettner M, Prinz B, Holz C, Stahl U, Lang C. High-throughput screening for expression of heterologous proteins in the yeast Pichia pastoris. J Biotechnol. 2002;99(1):51-62.
Damasceno LM, Huang C-J, Batt CA. Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol . 2012;93(1):31-39.
Damdinsuren B, Nagano H, Wada H, Kondo M, Ota H, Nakamura M, et al. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol. 2007;30(1):201-208.
Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochim Biophys Acta. 1999;1426(2):309-322.
Demolder J, Fiers W, Contreras R. Human interferon-beta, expressed in Saccharomyces cerevisiae, is predominantly directed to the vacuoles. Influence of modified co- expression of secretion factors and chaperones. J Biotechnol. 1994;32(2):179-189.
Eissazadeh S, Moeini H, Dezfouli MG, Heidary S, Nelofer R, Abdullah MP. Production of recombinant human epidermal growth factor in Pichia pastoris. Braz J Microbiol. 201748(2):286-293.
Han C, Su L, Hong R, Wu S, Wu J. A comparative study of maltooligosyltrehalose synthase from Sulfolobus acidocaldarius expressed in Pichia pastoris and Escherichia coli. Process Biochem. 2017;60:35-41.
Hotter DF, Kirchhoff F. Interferons and beyond: Induction of antiretroviral restriction factors. J Leukocyte Biol. 2018;103(3):465-477.
Hu H, Gao J, He J, Yu B, Zheng P, Huang Z, Mao X, Yu J, Han G, Chen D. Codon optimization significantly improves the expression level of a keratinase gene in Pichia pastoris. PLoS One. 2013;8(3):e58393.
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspect Med. 2018;a032003.
Kaskow BJ, Baecher-Allan C. Effector T Cells in multiple sclerosis. Cold Spring Harbor Perspect Med. 2018;a029025.
Kruger NJ. The Bradford method for protein quantitation. The protein protocols handbook, Springer: 2002;15-21.
Lassmann H. Multiple sclerosis pathology. Cold Spring Harbor Perspect Med. 2018;8(3):a028936.
Lilie H, Schwarz E, Rudolph R. Advances in refolding of proteins produced in E. coli. Curr Opin Biotechnol. 1998;9(5):497-501.
Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM. Heterologous protein production using the Pichia pastoris expression system. Yeast. 2005;22(4):249-270.
Medrano RF, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249.
Mobasher MA, Ghasemi Y, Montazeri-Najafabady N, Tahzibi A. Expression of recombinant IFN beta 1-b: a comparison between soluble and insoluble forms. Minerva Biotecnologica. 2016;28(1):39-43.
Morowvat MH, Babaeipour V, Rajabi-Memari H, Vahidi H, Maghsoudi N. Overexpression of recombinant human beta interferon (rhINF-β) in periplasmic space of Escherichia coli. Iran J Pharm Res. 2014;13(Suppl):151.
Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, et al. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res. 2007;27(6):507-516.
Rodriguez J, Spearman M, Huzel N, Butler M. Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions. Biotechnol Prog. 2005;21(1):22-30.
Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res. 1998;15(4):641-649.
Schmidt F. Recombinant expression systems in the pharmaceutical industry. Applied Microbiol Biotechnol. 2004;65(4):363-372.
Skoko N, Argamante B, Grujičić NK, Tisminetzky SG, Glišin V, Ljubijankić G. Expression and characterization of human interferon-β1 in the methylotrophic yeast Pichia pastoris. Biotechnol Appl Biochem. 2003;38(3):257-265.
Song K, Yoon I-S, Kim NA, Kim D-H, Lee J, Lee HJ, et al. Glycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic properties. PLoS ONE. 2014;9(5):e96967.
Utsumi J, Matsuo-Ogawa E, Nagahata T, Kasama K, Kagawa Y, et al. Carbohydrate-dependent biological activities of glycosylated human interferon-beta on human hepatoblastoma cells in vitro. Microbiol Immunol. 1995;39(1):81-86.
Von Kalckreuth V, Lohse AW, Schramm C. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis-not only beta interferon. Am J Gastroenterol. 2008;103(8):2147.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
